Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 11/20 | 0.53 |
| ▸ | MAPK12 | P53778 | 6/20 | 0.53 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.53 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.53 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.53 |
| ▸ | TNF | P01375 | 4/20 | 0.53 |
| ▸ | HCK | P08631 | 3/20 | 0.53 |
| ▸ | ABL1 | P00519 | 2/20 | 0.53 |
| ▸ | RAF1 | P04049 | 2/20 | 0.53 |
| ▸ | LYN | P07948 | 2/20 | 0.53 |
| ▸ | SRC | P12931 | 2/20 | 0.53 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.53 |
| ▸ | CIT | O14578 | 1/20 | 0.53 |
| ▸ | MUSK | O15146 | 1/20 | 0.53 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.53 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.53 |
| ▸ | STK10 | O94804 | 1/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.53 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6256613 | 0.92 | MAPK14 (0.47) | MAPK14MAPK12MAPK13MAPK11DDR2 | |
| SCHEMBL297067 | 0.87 | MAPK14 (0.55) | MAPK14MAPK12MAPK13MAPK11DDR2 | |
| SCHEMBL20876951 | 0.87 | MAPK14 (0.55) | MAPK14MAPK12MAPK13MAPK11DDR2 | |
| SCHEMBL28465474 | 0.84 | MAPK14 (0.62) | MAPK14MAPK12MAPK13MAPK11DDR2 | |
| SCHEMBL295782 | 0.82 | MAPK14 (0.65) | MAPK14MAPK12MAPK13MAPK11DDR2 | |
| SCHEMBL30335874 | 0.82 | MAPK14 (0.65) | MAPK14MAPK12MAPK13MAPK11DDR2 | |
| SCHEMBL370624 | 0.82 | MAPK14 (0.62) | MAPK14MAPK12MAPK13MAPK11DDR2 | |
| SCHEMBL6256612 | 0.81 | MAPK14 (0.34) | MAPK14MAPK12MAPK13MAPK11DDR2 | |
| SCHEMBL299835 | 0.79 | MAPK14 (0.68) | MAPK14MAPK12MAPK13MAPK11DDR2 | |
| SCHEMBL296092 | 0.79 | MAPK14 (0.62) | MAPK14MAPK12MAPK13MAPK11DDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1147104-B1 | AROMATIC HETEROCYCLIC COMPOUNDS AS ANTIINFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMA (US) | 2012-03-14 | — | — | EP | claimed |
| US-20070123516-A1 | Method of treating mucus hypersecretion | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2007-05-31 | — | — | US | claimed |
| EP-1709965-A2 | Methods of treating cytokine mediate diseases | Boehringer Ingelheim Pharmaceuticals, Inc. (US) | 2006-10-11 | — | — | EP | claimed |
| US-20040152725-A1 | Methods of treating cancer | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-08-05 | — | — | US | claimed |
| EP-1408950-A2 | METHODS OF TREATING CYTOKINE MEDIATED DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-04-21 | — | — | EP | claimed |
| US-20030220336-A1 | Method of treating mucus hypersecretion | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-11-27 | — | — | US | claimed |
| US-20030130309-A1 | Methods of treating cytokine mediated diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-07-10 | — | — | US | claimed |
| WO-2003005999-A2 | METHODS OF TREATING CYTOKINE MEDIATED DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-01-23 | — | — | WO | claimed |
| US-6329415-B1 | INHIBIT RELEASE OF INFLAMMATORY CYTOKINES SUCH AS INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2001-12-11 | — | — | US | claimed |
| EP-1147104-A1 | AROMATIC HETEROCYCLIC COMPOUNDS AS ANTIINFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2001-10-24 | — | — | EP | claimed |
| WO-2000043384-A1 | AROMATIC HETEROCYCLIC COMPOUNDS AS ANTIINFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2000-07-27 | — | — | WO | claimed |
| EP-4159212-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| US-20220282254-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | FULCRUM THERAPEUTICS INC (US) | 2022-09-08 | — | — | US | disclosed |
| US-20220133704-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | FULCRUM THERAPEUTICS INC (US) | 2022-05-05 | — | — | US | disclosed |
| US-11291659-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | Fulcrum Therapeutics, Inc. (US) | 2022-04-05 | — | — | US | disclosed |
| US-20020058678-A1 | Aromatic heterocyclic compounds as antiinflammatory agents | CIRILLO PIER F (US) | 2002-05-16 | — | — | US | disclosed |
| US-6372773-B1 | TREATMENT OF INFLAMMATION, ARTHRITIS WITH UREA OR THIOUREA HETEROCYCLES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-04-16 | — | — | US | disclosed |
| US-6333325-B1 | ADMINISTERING PYRAZOLE DERIVATIVE OF UREA OR THIOUREA FOR THERAPY OF CYTOKINE MEDIATED DISEASE SUCH AS ACTUATE AND CHRONIC PAIN, CONTACT DERMATITIS, ATHEROSCLEROSIS, GLOMERULONEPHRITIS, REPERFUSION INJURY, BONE RESORPTION | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2001-12-25 | — | — | US | disclosed |
| US-6329415-B1 | INHIBIT RELEASE OF INFLAMMATORY CYTOKINES SUCH AS INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2001-12-11 | — | — | US | disclosed |
| US-6319921-B1 | FOR TREATMENT OF RHEUMATOID ARTHRITIS, MULTIPLE SCLEROSIS, GUILLAIN-BARRE SYNDROME, CROHN'S DISEASE ULCERATIVE COLITIS, PSORIASIS, GRAFT VERSUS HOST DISEASE, SYSTEMIC LUPUS ERYTHEMATOSUS AND DIABETES | BOERHINGER INGELHEIM PHARMACEUTICALS, INC. | 2001-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220133704-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | ZFX, TBL1XR1, TRIM28 | MAPK14 191/4885MAPK12 436/4885MAPK13 303/4885 |
| US-20220282254-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | ZFX, TBL1XR1, TRIM28 | MAPK14 191/4885MAPK12 436/4885MAPK13 303/4885 |
| US-20030130309-A1 | Methods of treating cytokine mediated diseases | IL2, IFNG, IL1A | MAPK14 3143/4885MAPK12 3606/4885MAPK13 3752/4885 |
| US-20070123516-A1 | Method of treating mucus hypersecretion | MUC1, CFTR, MAPKAPK5 | MAPK14 44/4885MAPK12 50/4885MAPK13 49/4885 |
| US-20020058678-A1 | Aromatic heterocyclic compounds as antiinflammatory agents | FPR1, AHR, FPR2 | MAPK14 3755/4885MAPK12 3590/4885MAPK13 3792/4885 |
| US-11291659-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | ZFX, TBL1XR1, TRIM28 | MAPK14 191/4885MAPK12 436/4885MAPK13 303/4885 |
| US-20040152725-A1 | Methods of treating cancer | IL2, IL36G, IFNG | MAPK14 3691/4885MAPK12 3877/4885MAPK13 4084/4885 |
| US-20030220336-A1 | Method of treating mucus hypersecretion | MUC1, CFTR, MAPKAPK5 | MAPK14 44/4885MAPK12 50/4885MAPK13 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.